PRODUCTS SOLD ON PEPTIDESLABIRELAND.COM ARE FOR RESEARCH PURPOSES ONLY AND ARE NOT FOR HUMAN OR VETERINARY USE.
PRODUCTS SOLD ON PEPTIDESLABIRELAND.COM ARE FOR RESEARCH PURPOSES ONLY AND ARE NOT FOR HUMAN OR VETERINARY USE.
€253.00
Cagrilintide + Semaglutide Ireland – Buy Online | In Stock & Ready to Ship
Buy Cagrilintide + Semaglutide in Ireland with fast shipping and guaranteed ≥99% purity — verified with COA and HPLC documentation. A trusted choice for peptides Ireland research teams rely on, with no customs delays or international wait times. Whether you’re searching for Cagrilintide + Semaglutide Ireland suppliers or looking to buy peptides Ireland-wide, we have you covered. Irish research teams can count on consistent stock, rapid fulfilment and full batch documentation every time.
For research use only. Not intended for human or veterinary use.
Cagrilintide combined with Semaglutide — known in research as CagriSema — is the most potent dual amylin and GLP-1 receptor agonist combination in current obesity and metabolic research, producing greater weight reduction and metabolic improvement than either compound alone — available to buy in Ireland with fast dispatch and full batch documentation included.
CagriSema brings together two complementary and mechanistically distinct peptide pathways — amylin receptor activation via Cagrilintide and GLP-1 receptor activation via Semaglutide — in a research combination that has generated some of the most significant pre-clinical and clinical obesity data of any compound pairing currently under investigation. Researchers and institutions across Ireland can source verified, research-grade Cagrilintide and Semaglutide directly from our Irish peptide supply, with domestic-speed dispatch and complete batch documentation.
✅ ≥99% Purity — HPLC & Mass Spectrometry Verified
✅ Batch-Specific Certificate of Analysis (CoA) Included
✅ Sterile Lyophilised Powder | GMP Manufactured
✅ Fast Dispatch to Ireland | Peptides Ireland Stock
CagriSema is the research and clinical development name for the fixed combination of Cagrilintide and Semaglutide — two long-acting peptide analogues targeting separate but complementary hormonal systems involved in appetite regulation, energy balance, and metabolic control.
Cagrilintide is a long-acting synthetic analogue of amylin — a peptide hormone co-secreted with insulin from pancreatic beta cells in response to food intake. Amylin acts on AMY1, AMY2, and AMY3 receptors in the brainstem and hypothalamus to reduce appetite, slow gastric emptying, suppress post-meal glucagon release, and promote satiety. Cagrilintide is specifically engineered for once-weekly dosing through fatty acid acylation — the same half-life extension technology used in Semaglutide — making it the first long-acting amylin analogue suitable for weekly administration in clinical and pre-clinical research protocols.
Semaglutide is a long-acting GLP-1 receptor agonist — the gold-standard compound in GLP-1 pharmacology research and the most clinically validated obesity and type 2 diabetes research peptide currently available. It activates GLP-1 receptors in the pancreas, brain, and gastrointestinal tract to stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite through central hypothalamic and brainstem satiety signalling. Semaglutide’s once-weekly pharmacokinetic profile — achieved through albumin-binding fatty acid modification — has made it the benchmark long-acting GLP-1R agonist in both research and clinical contexts.
Together, Cagrilintide and Semaglutide activate two distinct receptor systems — amylin receptors and GLP-1 receptors — through separate but complementary neurohormonal pathways, producing additive to synergistic effects on appetite suppression, food intake reduction, gastric emptying, and metabolic regulation that exceed what either compound achieves independently.
In controlled laboratory, pre-clinical, and clinical research settings, the Cagrilintide and Semaglutide combination is studied across a broad range of obesity, metabolic, and hormonal biology research applications:
Dual Receptor Combination Pharmacology Research — The defining research application of CagriSema is studying the pharmacological interaction between amylin receptor and GLP-1 receptor activation — examining whether the two pathways produce additive or synergistic effects on appetite, food intake, body weight, and metabolic parameters, and what the mechanistic basis of any synergy is at the receptor, neuronal circuit, and systems biology level.
Obesity and Body Weight Reduction Research — CagriSema has been studied in pre-clinical and clinical obesity models as a combination approach to achieving greater body weight reduction than GLP-1 monotherapy. Studies have examined magnitude of weight loss, timeline, body composition changes, and durability of weight reduction in both pre-clinical and human research settings — with CagriSema producing weight loss data that has attracted significant scientific and clinical attention.
Appetite and Food Intake Research — Studies have examined how combined amylin and GLP-1 receptor activation affects appetite neurobiology — including hypothalamic and brainstem satiety circuit activity, meal size, meal frequency, and food preference in pre-clinical models — contributing to research on the neurohormonal regulation of energy intake and the complementary roles of amylin and GLP-1 signalling in appetite control.
Gastric Emptying Research — Both amylin and GLP-1 independently slow gastric emptying, and research has examined how combined Cagrilintide and Semaglutide treatment affects gastric emptying rate, nutrient absorption timing, and postprandial metabolic responses — contributing to understanding the gastrointestinal mechanisms through which the combination affects metabolic control.
Glucose Metabolism and Type 2 Diabetes Research — CagriSema has been studied for combined effects on glucose homeostasis — including fasting and postprandial glucose levels, HbA1c, insulin secretion, glucagon suppression, and insulin sensitivity in metabolic disease models — examining how dual amylin/GLP-1 activation compares to GLP-1 monotherapy for glycaemic research endpoints.
Body Composition Research — Beyond total weight reduction, studies have examined how CagriSema affects the composition of weight loss — specifically the ratio of fat mass to lean mass reduction — contributing to research on whether dual hormonal combination approaches preserve lean mass more effectively than single-agent obesity research compounds.
Cardiovascular Metabolic Research — Given Semaglutide’s established cardiovascular research profile and the metabolic benefits of weight reduction, studies have begun examining CagriSema’s effects on cardiovascular risk markers — including blood pressure, lipid profiles, inflammatory markers, and cardiac function parameters — in metabolically compromised pre-clinical and clinical research models.
Amylin Receptor Biology Research — Cagrilintide’s contribution to CagriSema makes this combination a valuable tool for studying amylin receptor pharmacology — examining how long-acting AMY receptor activation affects satiety neurobiology, brainstem circuit activity, and metabolic regulation in ways that complement and extend GLP-1 receptor-based research.
Incretin and Gut Hormone Combination Research — CagriSema contributes to the broader research field of gut hormone combination pharmacology — studying how pairing peptides from different hormonal systems produces superior metabolic outcomes to monotherapy, and what this reveals about the redundancy, complementarity, and synergy in the hormonal systems regulating energy balance.
Weight Loss Plateau and Durability Research — One research application of CagriSema is studying whether dual receptor activation can overcome the weight loss plateau commonly observed with GLP-1 monotherapy — examining the biological mechanisms behind weight loss plateau and whether activating a second hormonal pathway sustains progressive weight reduction beyond what a single system can achieve.
CagriSema has one of the most discussed and closely followed research and clinical development profiles in current obesity science:
Superior Weight Reduction vs Semaglutide Alone — Pre-clinical and early clinical studies have consistently reported that CagriSema produces greater body weight reduction than Semaglutide monotherapy at equivalent doses — with the combination delivering additive to potentially synergistic weight loss that has positioned it as the leading next-generation obesity research combination.
Landmark REDEFINE Clinical Trial Data — The REDEFINE clinical programme — studying CagriSema in human obesity research — has generated significant attention with reported weight reductions among the highest documented for any pharmacological intervention in clinical obesity research to date. Phase 3 data from this programme represents some of the most consequential obesity clinical research findings in recent years, with results establishing CagriSema as one of the most effective pharmacological approaches to weight reduction studied in human trials.
Complementary Mechanisms Confirmed — Research has confirmed that Cagrilintide and Semaglutide activate distinct receptor populations and neuronal circuits — with amylin receptor signalling concentrated in brainstem area postrema and nucleus tractus solitarius pathways, and GLP-1 receptor signalling additionally engaging hypothalamic circuits — supporting the mechanistic rationale for combination use and the basis for effects that exceed GLP-1 monotherapy.
Improved Glycaemic Control — Clinical and pre-clinical studies have documented significant improvements in glucose metabolism parameters — including HbA1c reduction and fasting glucose — with CagriSema, consistent with the combined glucoregulatory effects of amylin receptor and GLP-1 receptor co-activation and the metabolic benefits of greater weight reduction.
Body Composition Data — Studies have examined fat mass versus lean mass changes with CagriSema treatment — with research suggesting the combination produces predominantly fat mass reduction with relative preservation of lean mass, consistent with the expected effects of hormonally-mediated weight loss versus caloric restriction alone.
Favourable Tolerability Profile in Clinical Research — Clinical trial data has reported a tolerability profile broadly consistent with GLP-1 class compounds — with gastrointestinal effects representing the most commonly reported findings — and without new or unexpected safety signals attributable specifically to the addition of Cagrilintide to Semaglutide in the doses studied.
Pre-Clinical Synergy Data — Pre-clinical combination studies have reported evidence of synergistic rather than merely additive effects on body weight and food intake at certain dose combinations — with CagriSema producing greater than expected reductions based on the individual compound effects alone, supporting the hypothesis that amylin and GLP-1 receptor co-activation engages complementary neurobiological mechanisms.
| Feature | CagriSema | Tirzepatide | Semaglutide Alone | Retatrutide |
|---|---|---|---|---|
| Mechanism | GLP-1R + Amylin receptor (AMY1/2/3) | GLP-1R + GIPR | GLP-1R only | GLP-1R + GIPR + Glucagon R |
| Receptor Coverage | Dual — incretin + amylin | Dual — incretin | Single — incretin | Triple — incretin + glucagon |
| Appetite Pathways Engaged | Hypothalamic + brainstem (complementary circuits) | Hypothalamic (overlapping GLP-1/GIP circuits) | Hypothalamic | Hypothalamic + energy expenditure |
| Weight Loss Profile | Among highest reported in clinical obesity research | Significant — superior to semaglutide alone | Gold standard monotherapy | Very high — triple agonism |
| Glycaemic Research | Strong dual mechanism | Very strong — GIP enhances insulin | Strong | Strong |
| Key Research Distinction | Only amylin + GLP-1 combination | Only GLP-1 + GIP dual agonist | Gold standard GLP-1 reference | Only triple incretin + glucagon agonist |
| Stage of Research | Phase 3 clinical trials | Clinically approved | Clinically approved | Phase 3 clinical trials |
CagriSema is unique in being the only research combination targeting both the amylin receptor system and the GLP-1 receptor system — engaging brainstem and hypothalamic satiety circuits through complementary neurohormonal pathways that produce weight reduction exceeding GLP-1 monotherapy and representing a mechanistically distinct approach from GIP/GLP-1 dual agonism.
| Parameter | Detail |
|---|---|
| Name | Cagrilintide |
| Type | Long-acting synthetic amylin analogue |
| Target | AMY1, AMY2, AMY3 receptors |
| Half-Life | ~7 days (once-weekly dosing) |
| Mechanism | Amylin receptor activation — satiety / gastric emptying / glucagon suppression |
| Purity | ≥99% HPLC & MS Verified |
| Form | Sterile Lyophilised Powder |
| Storage (Powder) | -20°C, protect from light |
| Parameter | Detail |
|---|---|
| Name | Semaglutide |
| Type | Long-acting GLP-1 receptor agonist |
| Target | GLP-1 receptor |
| Half-Life | ~7 days (once-weekly dosing) |
| Mechanism | GLP-1R activation — insulin secretion / appetite suppression / gastric emptying |
| Purity | ≥99% HPLC & MS Verified |
| Form | Sterile Lyophilised Powder |
| Storage (Powder) | -20°C, protect from light |
Every order of Cagrilintide and Semaglutide in Ireland includes:
✅ Batch-Specific Certificate of Analysis (CoA) for each compound
✅ HPLC Chromatogram
✅ Mass Spectrometry Confirmation
✅ Sterility & Endotoxin Testing Report
✅ Reconstitution Protocol
✅ Technical Research Support
Can I buy Cagrilintide and Semaglutide in Ireland? Yes — we supply research-grade Cagrilintide and Semaglutide to researchers and institutions across Ireland with fast dispatch and full batch documentation for each compound. These compounds are supplied strictly for laboratory research purposes only.
What is CagriSema and why is it significant in obesity research? CagriSema is the combination of Cagrilintide — a long-acting amylin analogue — and Semaglutide — a long-acting GLP-1 receptor agonist. Its significance lies in combining two complementary hormonal pathways to achieve greater weight reduction and metabolic improvement than either compound alone. Clinical trial data from the REDEFINE programme has reported weight reductions among the highest documented for any pharmacological intervention in obesity research — making CagriSema one of the most closely followed compound combinations in current metabolic science.
How do Cagrilintide and Semaglutide work differently from each other? Semaglutide activates GLP-1 receptors primarily in the hypothalamus, brainstem, pancreas, and gastrointestinal tract — stimulating insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite through incretin signalling. Cagrilintide activates amylin receptors — particularly in the brainstem area postrema and nucleus tractus solitarius — reducing appetite, slowing gastric emptying, and suppressing post-meal glucagon through a separate neurohormonal pathway. The two compounds engage complementary neurological circuits and receptor systems, which is the mechanistic basis for their combined effects exceeding either alone.
How does CagriSema compare to Tirzepatide? Tirzepatide is a dual GLP-1R/GIPR agonist — combining GLP-1 and GIP receptor activation in a single molecule. CagriSema combines GLP-1 receptor activation with amylin receptor activation — a different receptor pairing that engages distinct neurobiological pathways. Both approaches produce weight reduction exceeding GLP-1 monotherapy, but through different mechanisms. CagriSema is the only combination engaging the amylin receptor system alongside GLP-1R, while Tirzepatide is the only approved dual GLP-1R/GIPR agonist — making them complementary rather than equivalent research tools for studying multi-receptor obesity pharmacology.
What is the REDEFINE trial and what did it find? REDEFINE is the Phase 3 clinical development programme studying CagriSema in human obesity research. Trial data has reported body weight reductions among the highest recorded for any pharmacological obesity intervention studied in clinical trials — establishing CagriSema as one of the most effective pharmacological approaches to weight reduction in clinical research and generating significant scientific interest in amylin/GLP-1 combination biology.
What purity is recommended for CagriSema research? ≥99% purity is strongly recommended for receptor binding assays, in vitro pharmacology, pre-clinical obesity models, and any research where compound quality directly affects receptor activation potency and reproducibility of metabolic endpoints. All Cagrilintide and Semaglutide Ireland stock is independently verified to ≥99%.
How do I reconstitute Cagrilintide and Semaglutide for laboratory use? Allow each vial to reach room temperature before opening. Both compounds reconstitute in sterile water or bacteriostatic water — add solvent slowly down the inside wall of the vial and swirl gently without shaking. Use promptly after reconstitution or aliquot and store at -80°C to preserve peptide integrity and biological activity. Prepare each compound as a separate stock solution and combine at working concentration as required by the research protocol.
Cagrilintide and Semaglutide are supplied exclusively for legitimate scientific research purposes conducted within licensed laboratory environments. These products are not intended for human consumption, self-administration, or any therapeutic application. They must be handled by qualified researchers in compliance with applicable Irish and EU regulations and institutional ethics guidelines. By purchasing, you confirm that these compounds will be used solely for approved in-vitro or pre-clinical research purposes.
Receive News
